European Commission Approved Rinvoq for Pediatric Arthritis
The regulatory body authorized the drug for children two years and older with active polyarticular juvenile idiopathic arthritis.
Updated on Sept. 30, 2026 in Arthritis
Live Poll
Do you support the authorization of new medical treatments for pediatric patients with chronic conditions?
The European Commission has approved Rinvoq as a treatment for pediatric patients aged two and older suffering from active polyarticular juvenile idiopathic arthritis. The authorization includes both a 15 mg tablet and a new weight-based oral solution for those who have responded inadequately to previous disease-modifying antirheumatic drugs.
Why it matters
This approval provides a new therapeutic option for children with chronic joint inflammation, specifically targeting patients who have failed or could not tolerate standard treatments. It expands the reach of the medication to address a condition that affects approximately 126,000 children across Europe.
The approval is supported by the phase 1 SELECT-YOUTH study, which evaluated efficacy and tolerability in patients aged two to 17. Rinvoq is now approved in the European Union for 11 distinct immune-mediated, inflammatory indications.
The players
European Commission
The European Commission serves as the executive branch of the European Union, responsible for proposing legislation, implementing decisions, and managing the EU's day-to-day business.
Rinvoq
Rinvoq is a medication used to treat various immune-mediated inflammatory diseases by inhibiting Janus kinase enzymes to reduce inflammation.
The details
Polyarticular juvenile idiopathic arthritis is characterized by inflammation in five or more joints persisting for at least six weeks. The new treatment delivery methods, including the oral solution, are designed to accommodate the varying weight-based needs of pediatric patients.
Timeline
Week 12 marked the initial observation of treatment efficacy during the clinical study.
Week 48 saw continued improvements in patient response rates.
The Big Picture
This regulatory decision follows a pattern established by the phase 1 SELECT-YOUTH study, which demonstrated the safety and efficacy profile required for pediatric use. The expansion of Rinvoq into juvenile arthritis underscores the trend of adapting adult inflammatory therapies for younger patient populations.
Patients and caregivers now have access to both 15 mg tablets and a weight-based oral solution tailored for younger children. This development offers a new pathway for those who have exhausted traditional DMARD treatment options.
The takeaway
This approval marks a significant shift in pediatric rheumatology by introducing JAK inhibitor therapy for younger patients. Caregivers should consult with pediatric specialists to determine if this new formulation is appropriate given a child's specific treatment history.
Further reading
For more on treatment options, visit the Arthritis section.
Source note: This article includes information reported by PharmaTimes.
Live Poll
Do you support the authorization of new medical treatments for pediatric patients with chronic conditions?
